Predicting future years of healthy life for older adults

Journal of Clinical Epidemiology

Volumn 51, Issue 4, 1998, Pages 343-353

  Diehr, Paula ^a   Patrick, Donald L ^a   Bild, Diane E ^b   Burke, Gregory L ^c   Williamson, Jeff D ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aged; Clinical trials; Cost benefit; Discounting; Health status; Healthy life expectancy; QALY; Survival

Indexed keywords

AGED; ARTICLE; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LONGITUDINAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR;

EID: 0032055508     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(97)00298-9     Document Type: Article

References (28)

1. 1. Patrick DL, Erickson P. Health Status and Health Policy: Allocating Resources to Health Care. New York: Oxford University Press; 1993.
2. 2. Patrick D, Beresford S, Ehreth J, Diehr P, Picciano J, Durham M, Grembowski D. Interpreting excess mortality in a prevention trial for older adults. Int J Epidemiol 1995; 24: S27-S33.
3. 3. Rawles J, Light J. Loss of quality adjusted days as a trial endpoint: Effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT). J Epidemiol Community Health 1993; 47(5): 377-381.
4. 4. Levin LA, Jonsson B. Cost-effectiveness of thrombolysis - a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 1992; 13: 2-8.
5. 5. Weinstein MC, Tosteson ANA. Cost-effectiveness of hormone replacement. Ann NY Acad Sci 1990; 592: 162-172.
6. 6. Thompson MS, Read JL, Hutchings HC, et al. The cost-effectiveness of auranofin: Results of a randomized clinical trial. J Rheumatol 1988; 15: 35-42.
7. 7. Oster G, Huse DM, Delea TE, Colditz GA. Cost-effectiveness of nicotine chewing gum as an adjunct to physician's advice against cigarette smoking. JAMA 1986; 256: 1315-1318.
8. 8. Gold M, Siegel J, Weinstein M, Russell L, Eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
9. 9. Krause NM, Jay GM. What do global self-rated health items measure? Med Care 1994; 32: 930-942.
10. 10. Gold M, Franks P, Erickson P. Assessing the health of the nation: The predictive validity of a preference-based measure and self-rated health. Medical Care 1996; 34: 163-177.
11. 11. Idler EL, Benyamini Y. Self-rated health and mortality: A review of twenty-seven community studies. J Health Soc Behav 1997; 38: 21-37.
12. 12. Diehr P, Patrick D, Hedrick S, Rothman M, Grembowski D, Raghunathan TE, Beresford S. Including deaths when measuring health status over time. Med Care 1995; 33: AS164-AS172.
13. 13. Vital and Health Statistics. Americans Assess Their Health: United States, 1987. Series 10. Data from the National Health Interview Survey. No. 174. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, Center for Disease Control, National Center for Health Statistics; 1990.
14. 14. Mossey JM, Shapiro E. Self-rated health: A predictor of mortality among the elderly. AJPH 1982; 72: 800-808.
15. 15. Kaplan GA, Camacho T. Perceived health and mortality: A nine-year follow-up of the human population laboratory cohort. Am J Epidemiol 1983; 117: 292-304.
16. 16. Fairclough D. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997; 16: 1197-1210.
17. 17. Diehr P, Patrick DL, Psaty B. Effect size and power for clinical trials that measure years of healthy life. Stat Med 1997; 16: 1211-1224.
18. 18. Durham M, Beresford S, Diehr P, Grembowski D, Hecht J, Patrick D. Participation of higher users in a randomized trial of Medicare reimbursement for preventive services. Gerontologist 1991; 31: 603-606.
19. 19. Fried L, Nemar O, Enright P, et al. The cardiovascular health study: Design and rationale. Annals Epidemiol 1991; 1: 263-276.
20. 20. Ives G, Fitzpatrick A, Bild D, et al. Surveillance and ascertainment of cardiovascular events: The cardiovascular health study. Annals Epidemiol 1995; 5: 278-285.
21. 21. Parzen E. Modern Probability Theory and its Applications. New York: John Wiley and Sons; 1960.
22. 22. Rogers A, Rogers RG, Branch LG. A multistate analysis of active life expectancy. Public Health Reports 1989; 104: 222-226.
23. 23. Vital Statistics of the United States, 1989. Vol. II - Mortality. Part A. Hyattsville, MD: U.S. Department of Health and Human Services, Public Health Service, Center for Disease Control and Prevention, National Center for Health Statistics; 1993.
24. 24. Erickson P, Wilson R, Shannon I. Years of Healthy Life. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics. Healthy People 2000 Statistical Notes. Number 7. April 1995.
25. 25. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
26. 26. Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1995; 5: 270-277.
27. 27. McHorney CA. Measuring and monitoring general health status in elderly persons: Practical and methodological issues in using the SF-36 Health Survey. Gerontologist 1996; 36: 571-583.
28. 28. Kaplan RM, Anderson JP. An integrated approach to quality of life assessment: The general health policy model. In: Spilker B, Ed. Quality of Life Assessments in Clinical Trials. New York: Raven Press; 1990.